Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
The diagnosis of melanoma begins with a thorough clinical examination. Dermatologists use a specialized tool called a dermatoscope to evaluate pigmented lesions. A dermatoscope is a handheld device that provides magnification and non-polarized or polarized light. This allows the physician to see through the stratum corneum (the dead outer layer of skin) and visualize structures in the epidermis and upper dermis that are invisible to the naked eye.
Dermatoscopy reveals specific patterns associated with malignancy. These include an atypical pigment network, irregular streaks or globules, blue-white veil structures (indicating regression or fibrosis), and atypical vascular patterns. Using dermatoscopy significantly increases the sensitivity and specificity of melanoma diagnosis compared with naked-eye examination alone, reducing unnecessary biopsies of benign moles while detecting subtle melanomas earlier.
For patients with a large number of moles or a personal history of melanoma, Total Body Photography (TBP) may be employed. This involves taking high-resolution baseline photographs of the patient’s entire skin surface. At follow-up visits, these photos serve as a map to identify new lesions or subtle changes in existing ones. Digital mole mapping takes this a step further, using software to track dermoscopic images of specific moles over time.
When a lesion is suspected to be melanoma, a biopsy is mandatory to confirm the diagnosis. The goal of the biopsy is to remove the entire visible lesion with a narrow margin of normal skin, while preserving the ability to perform accurate staging later. An excisional biopsy is the gold standard. In this procedure, the surgeon cuts out the entire lesion, usually in an elliptical shape, ensuring the full depth of the skin is sampled.
This is critical because the most important prognostic factor is the Breslow depth—the thickness of the tumor. An excisional biopsy provides the pathologist with the entire architecture of the cancer, allowing for precise measurement of thickness. Partial biopsies, such as shave biopsies or punch biopsies, may be used in specific anatomical locations (like the face or nail unit) or for extensive lesions. Still, they carry the risk of underestimating the tumor depth if the thickest part of the cancer is not sampled or if the base of the tumor is transected.
The biopsy specimen is sent to a pathology laboratory where it is fixed, stained, and examined under a microscope. The pathologist confirms the melanocytic origin of the cells and assesses for features of malignancy.
The pathology report determines the next steps in management. The most critical metric reported is the Breslow Thickness, measured in millimeters from the top of the epidermal granular layer to the deepest point of tumor invasion. Thinner melanomas (less than 1mm) have a very high survival rate, while thicker melanomas carry a higher risk of metastasis.
Other critical histological features include Ulceration. This refers to the loss of the epidermis over the tumor. The presence of ulceration is a sign of rapid growth and biological aggression; it automatically upstages the tumor and worsens the prognosis. The Mitotic Rate measures how actively the cells are dividing (mitoses per square millimeter). A higher mitotic rate indicates a faster-growing tumor.
The pathologist also reports on Microsatellites (tiny nests of tumor cells slightly away from the central mass), Lymphovascular Invasion (tumor cells seen within blood vessels or lymph channels), and the status of the surgical margins (whether the cancer extends to the edge of the sample). The Clark Level describes the anatomical layer of invasion (e.g., papillary vs. reticular dermis) but has largely been superseded by Breslow thickness for staging purposes.
Melanoma spreads primarily through the lymphatic system. The first lymph node that drains fluid from the area of the skin where the melanoma is located is called the Sentinel Lymph Node (SLN). The status of this node is the most powerful predictor of survival.
For melanomas that meet specific criteria (typically Breslow thickness greater than 0.8mm or thinner melanomas with ulceration), a Sentinel Lymph Node Biopsy is offered. This is a surgical staging procedure performed at the same time as the wide excision of the primary tumor site.
The procedure involves injecting a radioactive tracer and/or a blue dye near the melanoma site. These tracers travel through the lymph channels to the sentinel node. Using a gamma probe and visual inspection, the surgeon locates this specific node (or nodes), removes it, and sends it to pathology. If the sentinel node is free of cancer, likely that the other nodes are also clear, and the patient avoids a complete lymph node dissection. If the sentinel node contains cancer cells (micro-metastasis), it indicates Stage III disease and changes the treatment plan to include systemic therapy.
Melanoma is staged using the TNM system (Tumor, Node, Metastasis) maintained by the American Joint Committee on Cancer (AJCC).
T-Stage is based on Breslow thickness and ulceration.
N-Stage reflects the number of positive lymph nodes and whether they are palpable (felt on exam) or occult (only seen under a microscope).
M-Stage indicates distant spread to skin, lung, or other organs, and also incorporates Lactate Dehydrogenase (LDH) levels in the blood. Elevated LDH is a marker of high tumor burden and poor prognosis.
For early-stage melanoma, cross-sectional imaging (CT or PET/CT) is generally not required as the risk of distant spread is low. However, for patients with positive lymph nodes or symptoms suggestive of metastasis, imaging is crucial. PET/CT scans are highly sensitive for detecting metabolic activity in distant organs. MRI of the Brain is mandatory for advanced stages because melanoma has a unique predilection for spreading to the brain.
Send us all your questions or requests, and our expert team will assist you.
A shave biopsy removes the top layer of the skin lesion using a blade. While quick, it often misses the deep part of the tumor, making it impossible to measure the actual thickness (Breslow depth). An excisional biopsy removes the entire lesion and some surrounding tissue, allowing the pathologist to measure the full depth, which is vital for accurate staging.
Breslow depth is the measurement, in millimeters, of how deep the melanoma has grown into the skin. It is measured from the skin surface to the deepest cancer cell. This number is the most critical factor in predicting the outcome. Thinner tumors have a better prognosis than thicker ones.
The primary purpose of a Sentinel Lymph Node Biopsy is diagnostic, not curative. It tells the doctor if the cancer has spread. However, removing a positive node does remove some cancer burden. If the node is positive, it guides the decision to use additional treatments, such as immunotherapy, to help cure the disease.
Lactate Dehydrogenase (LDH) is an enzyme found in cells. When cancer cells grow rapidly or die, they release LDH into the blood. In advanced melanoma, high LDH levels usually mean the cancer has spread widely and is aggressive. It is used as part of the staging system for Stage IV disease.
Usually, no. If you have a thin melanoma (Stage I) and no symptoms, the chance that the cancer has spread to distant organs is exceptionally low. Scans in this situation often find harmless lumps that cause unnecessary worry and more testing. Scans are reserved for higher-risk or advanced stages.
Your Comparison List (you must select at least 2 packages)
